Revance Therapeutics Inc (RVNC) - Cash per Single Share

Symbol and logo of brand Revance Therapeutics Inc (RVNC)

Revance Therapeutics (RVNC) is driving capital growth through the strong pricing power of its long-acting Daxxify, a trend supported by the cash per share history, where the latest figure stands at 1.75. Patent protection and physician loyalty create a robust barrier to entry for competitors. The company is currently completing an autonomous development cycle as it prepares for a merger with a major industry behemoth.

RVNC Revance Therapeutics Inc.: Cash per Single Share in the range 07/04/2022 - 02/16/2025

Comprehensive metric breakdowns and analytics for Revance Therapeutics, Inc. (RVNC)

- cash and cash flow data:
Summary company analysis:RVNC (Revance Therapeutics Inc)
Finished products of revance.com

This indicator reflects the issuer's net liquidity, representing the volume of free cash flow per share minus all liabilities. The annual trend of cash per share demonstrates the ability of Revance Therapeutics (RVNC) to fund the expansion of Daxxify and fillers without resorting to external borrowing. The growth of this reserve confirms the stability of settlements with clinics and dermatologists. However, an excessive balance may indicate inefficient capital allocation. This metric serves as a reliable safeguard against default during periods of market stagnation.